The Personalized Therapy Biosimulation Platform segmentation by application delineates four primary use cases: drug discovery, clinical trial design, regulatory submission, and post‑market surveillance. The drug discovery segment, accounting for roughly 35 % of total revenue, leverages in‑silico modeling to prioritize candidate molecules, thereby reducing wet‑lab cycles and capital outlay. Clinical trial design, representing about 30 % of the market, employs patient‑specific virtual cohorts to optimize dosing regimens and enrollment criteria, which directly influences trial success rates and cost efficiency. Regulatory submission, with a 20 % share, provides validated simulation data that satisfy agency expectations for efficacy and safety, shortening review timelines. Post‑market surveillance, contributing the remaining 15 %, uses real‑world data integration to monitor therapeutic outcomes and support label extensions. Collectively, these categories define the market taxonomy and explain the distribution of investment across the Personalized Therapy Biosimulation Platform market.